162 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
8-K
EX-99.1
jhkldvhm5isqbc
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
4v3x5vdw7dz762
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T
EX-99
52tp2lvd56b20
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
u2poul7zzi7 00
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
fmr3fary9b7n3
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-99.1
hik uamwd39c27rfgtwi
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
CORRESP
ipx0pe2xj3 zrn
7 Oct 22
Correspondence with SEC
12:00am
UPLOAD
9ow52cbj2y0ty 7z76
21 Sep 22
Letter from SEC
12:00am